These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37625815)

  • 1. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
    Berenguer-Ruiz S; Aparicio-Domínguez M; Herranz-Pinto P; Ruíz-Villaverde R; López-Ferrer A; Santos-Juanes J; Rodríguez Fernández-Freire L; Hospital-Gil M; Arias-Santiago S; Carretero-Hernández G; Mateu-Puchades A; Ferran M; Del Alcázar E; Santos-Alarcón S; Garcia-Latasa de Aranibar FJ; Belinchón-Romero I; González-Cantero Á; Ruíz-Genao D; Eiris-Salvado N; Rocamora-Durán V; Rivera-Diaz R; de la Cueva P; Daudén E; Salgado-Boquete L; Llamas-Velasco M;
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2517-2525. PubMed ID: 37625815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
    Narcisi A; Valenti M; Gargiulo L; Ibba L; Amoruso F; Argenziano G; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Franchi C; Girolomoni G; Guarneri C; Loconsole F; Sampogna F; Travaglini M; Malagoli P; Costanzo A
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):93-103. PubMed ID: 36156312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis.
    Heim J; Vasquez JG; Bhutani T; Koo J; Mathew J; Gogineni R; Ferro T; Bhatia N
    J Drugs Dermatol; 2024 Aug; 23(8):612-618. PubMed ID: 39093661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis.
    Di Brizzi EV; Buononato D; Benvenuto P; Argenziano G; De Pasquale R; Fiorella CS; Giofrè C; Musumeci ML; Palazzo G; Zichichi L; Balato A
    Dermatol Pract Concept; 2023 Oct; 13(4):. PubMed ID: 37992389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study.
    Heim J; Vasquez JG; Schenkel B; Bhatia N
    J Drugs Dermatol; 2023 Aug; 22(8):754-760. PubMed ID: 37556515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience.
    Melgosa Ramos FJ; Mateu Puchades A; Matáix-Díaz J; Schneller-Pavelescu L; Belinchón-Romero I; Santos Alarcón S
    Actas Dermosifiliogr; 2024; 115(7):722-726. PubMed ID: 38556201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients.
    Drerup KA; Seemann C; Gerdes S; Mrowietz U
    Dermatology; 2022; 238(4):615-619. PubMed ID: 34775387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
    Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
    J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
    Caldarola G; Galluzzo M; Bernardini N; Calabrese L; Grimaldi M; Moretta G; Pagnanelli G; Shumak RG; Talamonti M; Tofani L; Pallotta S; Peris K; Potenza C; De Simone C; Campione E
    Dermatol Ther; 2022 Jun; 35(6):e15488. PubMed ID: 35384168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of tildrakizumab on quality of life in patients suffering from moderate-to-severe psoriasis: a 36-week prospective, monocentric, real-life, observational study.
    Cacciapuoti S; Battista T; Potestio L; Scalvenzi M; Megna M; Ruggiero A
    Clin Exp Dermatol; 2024 Oct; ():. PubMed ID: 39400048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
    Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients.
    Campione E; Lambiase S; Gaeta Shumak R; Galluzzo M; Lanna C; Costanza G; Borselli C; Artosi F; Cosio T; Tofani L; Dattola A; Di Daniele F; Bianchi L
    Pharmaceuticals (Basel); 2023 Mar; 16(4):. PubMed ID: 37111283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tildrakizumab in Complex Psoriatic Patients: An Experience in Emilia-Romagna (Italy).
    Bardazzi F; Viviani F; Piraccini BM; Lasagni C; Bigi L; Manfredini M; Pongetti L; Di Lernia V; Corazza M; Pepe F
    J Cutan Med Surg; 2023; 27(2):126-132. PubMed ID: 36995351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis patients' characteristics associated with high PASI response to tildrakizumab: an international dual center study.
    Burlando M; Maul JT; Salvi I; Simic D; Cozzani E; Ak M; Birkenmaier I; Parodi A
    Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6772-6776. PubMed ID: 36196725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting.
    Bhatia N; Heim J; Vasquez JG; Bhutani T; Schenkel B; Gogineni R; Koo J
    J Dermatolog Treat; 2024 Dec; 35(1):2310631. PubMed ID: 39038815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
    Del Alcázar E; López-Ferrer A; Martínez-Doménech Á; Ruiz-Villaverde R; Llamas-Velasco MDM; Rocamora V; Julià M; Notario J; Fernández-Freire LR; Sahuquillo-Torralba A; Vidal D; Rivera R; Carretero G; Mateu A; de la Cueva P; Carrascosa JM
    Dermatol Ther; 2022 Feb; 35(2):e15231. PubMed ID: 34820971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis.
    Elgaard CDB; Iversen L; Hjuler KF
    J Dermatolog Treat; 2023 Dec; 34(1):2133531. PubMed ID: 36200762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
    Reich K; Warren RB; Iversen L; Puig L; Pau-Charles I; Igarashi A; Ohtsuki M; Falqués M; Harmut M; Rozzo S; Lebwohl MG; Cantrell W; Blauvelt A; Thaçi D
    Br J Dermatol; 2020 Mar; 182(3):605-617. PubMed ID: 31218661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.